Heart failure & cardiomyopathiesSecondary analysis
Distinct Comorbidity Clusters in Patients With Acute Heart Failure
- Secondary analysis of the RELAX-AHF-2 randomised trial
- latent class analysis
- external validation in RELAX-AHF
Authors' conclusion
Comorbidities naturally clustered into 5 mutually exclusive groups in RELAX-AHF-2, showing variations in clinical outcomes.
Study context
- Population
- Patients with acute HF in RELAX-AHF-2 (26% HFpEF, LVEF ≥50%)validation n = 1,161
- Participants
- 6,545 patients
- Comparison
- Multimorbidity clusters vs young cluster
- Primary endpoint
- Composite outcome
Primary result
As reported in the abstract
Composite outcome (adjusted)
Each group vs youngHazard ratio (95% CI)
Diabetes and CKD
1.80(1.50–2.20)
Elderly/AF
1.42(1.20–1.70)
Metabolic
1.40(1.20–1.80)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause mortality, Young cluster (serelaxin-treated) · young group | 0.59 (0.40–0.90) | |
| 0.512Hazard ratio (log scale) |
Effect modification by treatment allocation (placebo or serelaxin)
- Treatment allocation modified associations
- P for interaction < 0.001
- interaction P <0.001
Validation in RELAX-AHF
- Patients clustered in 5 multimorbidity groups; characteristics and outcome associations validated
Original publication
Distinct Comorbidity Clusters in Patients With Acute Heart Failure. JACC Heart Fail. Published 3 July 2024. doi:10.1016/j.jchf.2024.04.028
Summarised from the published abstract; every number is checked against it